The Inflation Reduction Act: Implications for Patient Access in CL

Video content above is prompted by the following question(s):

1. What efforts are being made to improve affordability and access to BTK inhibitors for all patients who could benefit from them?

1. Ibrutinib was selected for the first round of Medicare drug price negotiations, a key component of the Inflation Reduction Act (IRA). How might this negotiation impact patient access to BTK inhibitor therapy?